Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
|Articles|July 1, 1998
Supplements and Featured Publications
- New and Emerging Therapies in the Treatment of Hypertension and Congestive Heart Failure
- Volume 4
- Issue 7 Suppl
What are the Pharmacological Differences Between Angiotensin II Antagonists
Author(s)Thomas Unger, MD
Advertisement
Articles in this issue
over 28 years ago
Participating Facultyover 28 years ago
Gene Polymorphism Influences Response to Angiotensin Blockadeover 28 years ago
New Drug Class Offers Benefits in Heart Failureover 28 years ago
Exploring the Benefits Beyond Blood Pressure ControlAdvertisement
Related to this article
Kidney Week 2026 abstracts show that AMKD progresses quickly in routine practice, with or without diabetes, despite background CKD therapy.
Insurance barriers were the top reason 4 in 10 people prescribed long-acting PrEP at a Missouri clinic never received it, an IDWeek 2026 poster found.
A retrospective study suggests strength exercise may be a safer option than endurance exercise for some people with ACM.
Infant flu protection from maternal vaccination varied by timing, while pediatric vaccination fell to 49.4%, experts report at IDWeek 2026.
The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.
Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
The pilot pairs grocery stipends and community health worker support with members who have unmanaged diabetes and unmet social needs.
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
3
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
4
Extension Studies in TPIP Show Promise in PAH, PH-ILD
5